Breast Cancer

A study of African American women found that drinking 7 or more alcoholic drinks a week was associated with an elevated risk for breast cancer of all subtypes.

The 2013 ASCO/CAP updates to HER2 testing guidelines did not result in changes to the rate of HER2 positivity among breast cancer patients.

Results of a new study suggest that breast cancer–related lymphedema is strongly associated with multimodality treatment, including chemotherapy, and not axillary node surgery alone.

Trimodality therapy achieved improved locoregional control among a cohort of women with nonmetastatic inflammatory breast cancer.

Women who undergo bilateral mastectomy for the treatment of DCIS may be overtreated, according to the results of a new study.

A new study is suggesting that testing for variants in seven cancer-associated genes followed by risk-reduction management could cost-effectively improve life expectancy for women at risk for hereditary breast cancer.

Adding the PARP inhibitor veliparib to carboplatin and paclitaxel chemotherapy regimens failed to prolong overall survival in lung and breast cancers.

Trastuzumab plus low-dose radiotherapy does not have a significant effect on left ventricular ejection fraction changes in HER2-positive breast cancer.

Mateusz Opyrchal, MD, PhD, talks about how the Inhibition of AURKA induces Raf1-independent activation of MAPK pathway in breast cancer cells.

Administration of dexrazoxane along with adjuvant chemotherapy was cardioprotective in patients with HER2-positive breast cancer treated with chemotherapy followed by 1 year of trastuzumab maintenance therapy.

PARP inhibitors are an active, novel, and exciting class of anticancer agents. They have shown clear patient benefit in gBRCA, HR-deficient, and other ovarian cancers.

A 48-year-old Caucasian woman presented with a palpable right breast mass. Physical examination confirmed a lump on the upper outer quadrant of her right breast. On PET/CT scan there was an incidental finding of increased metabolic activity in the left lateral breast.

Women with breast cancer who sleep for longer every night, and who report regular sleep difficulties, had higher all-cause and breast cancer mortality.

In this interview we discuss long-term data on the anti–PD-L1 immunotherapy atezolizumab in metastatic triple-negative breast cancer.

We spoke with Dr. Gerald Falchook about the first human study of a first-in-class molecule, fatty acid synthase inhibitor known as TVB-2640 for advanced solid tumors.

In this interview we discuss the use of CTCs and circulating tumor DNA for prognosis and disease monitoring in patients with breast cancer.

Among women with nonmetastatic breast cancer, obesity was associated with poorer outcomes only among those with luminal A cancers based on PAM50 gene expression analysis, according to a new study.

A database analysis found that facility-level factors such as location contribute more than patient-level factors to the underuse of guideline-recommended therapy for nonmetastatic inflammatory breast cancer.

A new population-based study is suggesting that there are significant racial disparities in gene expression profiling testing in women with breast cancer.

The FDA has approved ribociclib in combination with an aromatase inhibitor for the first-line treatment of postmenopausal women with advanced, HR-positive/HER2-negative breast cancer.

The ASCO-CAP guidelines for HER2 gene amplification testing leave some patients at risk for misclassification and inappropriate treatment.

Scientists from Dana-Farber Cancer Institute found that a compound that can reverse the function of innate immune system cells-to fight tumors rather than encourage growth-caused breast tumors in mice to shrink and withdraw from distant metastases.

Surgical oncologists can help reduce the risk of patients developing opioid dependence.

Breast conservation therapy is usually best for local treatment for stage II breast cancer-and biology, as well as stage, drives patient outcomes.

Despite breast tumors’ lower mutational loads than lung cancers and melanoma-cancers in which immunotherapy have shown particular promise-breast cancers are nevertheless immunogenic.

The United States Medicare Access and CHIP Reauthorization Act of 2015 quality- and payment-related provisions took effect January 1, 2017, and how oncologists comply this year will determine their payments in 2019.

Refining the American Joint Committee on Cancer breast cancer staging system to include molecular tumor markers will improve patient risk stratification and determination of prognosis.

Timing remains an important challenge for breast reconstruction in patients undergoing radiation therapy and surgery for breast cancer.

Recent findings have raised doubts about the promise of whole-brain radiation therapy against metastatic brain tumors for patients with advanced breast cancer.

Breast surgeons can and should provide genetic counseling to their patients because the need outstrips the availability of genetic counselors.